GB201615917D0 - Pharmaceutical composition - Google Patents
Pharmaceutical compositionInfo
- Publication number
- GB201615917D0 GB201615917D0 GBGB1615917.0A GB201615917A GB201615917D0 GB 201615917 D0 GB201615917 D0 GB 201615917D0 GB 201615917 A GB201615917 A GB 201615917A GB 201615917 D0 GB201615917 D0 GB 201615917D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- pharmaceutical composition
- pharmaceutical
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (46)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1615917.0A GB2558191A (en) | 2016-09-19 | 2016-09-19 | Pharmaceutical composition |
| US16/334,158 US10888546B2 (en) | 2016-09-19 | 2017-09-18 | Pharmaceutical composition |
| MYPI2019001316A MY202069A (en) | 2016-09-19 | 2017-09-18 | Pharmaceutical composition |
| ES21183659T ES2957459T3 (en) | 2016-09-19 | 2017-09-18 | Pharmaceutical composition comprising glycopyrrolate |
| KR1020217021521A KR20210089273A (en) | 2016-09-19 | 2017-09-18 | Pharmaceutical composition |
| MX2019003098A MX387723B (en) | 2016-09-19 | 2017-09-18 | PHARMACEUTICAL COMPOSITION COMPRISING GLYCOPYRRONIUM BROMIDE, FLUTICASONE PROPIONATE AND 1,1-DIFLUOROETHANE. |
| ES19199780T ES2968212T3 (en) | 2016-09-19 | 2017-09-18 | Pharmaceutical composition comprising glycopyrrolate |
| JP2019515227A JP6781829B2 (en) | 2016-09-19 | 2017-09-18 | Pharmaceutical composition |
| CA3037092A CA3037092C (en) | 2016-09-19 | 2017-09-18 | Stable pharmaceutical compositions comprising glycopyrrolate and 1,1-difluoroethane (hfa-152a) suitable for use in metered dose inhalers (mdis) |
| CN202210090188.8A CN114272238A (en) | 2016-09-19 | 2017-09-18 | Pharmaceutical composition |
| EP17777635.8A EP3515432B1 (en) | 2016-09-19 | 2017-09-18 | Pharmaceutical composition comprising glycopyrrolate |
| PE2019000674A PE20191043A1 (en) | 2016-09-19 | 2017-09-18 | PHARMACEUTICAL COMPOSITION |
| ES17777635T ES2892673T3 (en) | 2016-09-19 | 2017-09-18 | Pharmaceutical composition comprising glycopyrrolate |
| CN202210401223.3A CN114712338A (en) | 2016-09-19 | 2017-09-18 | pharmaceutical composition |
| KR1020197010385A KR102277635B1 (en) | 2016-09-19 | 2017-09-18 | pharmaceutical composition |
| NZ752430A NZ752430B2 (en) | 2016-09-19 | 2017-09-18 | Pharmaceutical composition |
| AU2017328907A AU2017328907B2 (en) | 2016-09-19 | 2017-09-18 | Pharmaceutical composition |
| GEAP201715035A GEP20217239B (en) | 2016-09-19 | 2017-09-18 | Pharmaceutical composition |
| PCT/GB2017/052761 WO2018051130A1 (en) | 2016-09-19 | 2017-09-18 | Pharmaceutical composition |
| ES19199783T ES2968453T3 (en) | 2016-09-19 | 2017-09-18 | Pharmaceutical composition comprising glycopyrrolate |
| EP19199783.2A EP3610871B1 (en) | 2016-09-19 | 2017-09-18 | Pharmaceutical composition comprising glycopyrrolate |
| EP21183659.8A EP3915555B1 (en) | 2016-09-19 | 2017-09-18 | Pharmaceutical composition comprising glycopyrrolate |
| PH1/2019/500579A PH12019500579B1 (en) | 2016-09-19 | 2017-09-18 | Pharmaceutical composition |
| MX2021009476A MX392213B (en) | 2016-09-19 | 2017-09-18 | PHARMACEUTICAL COMPOSITIONS COMPRISING GLYCOPYRROLATE SALTS AND 1,1-DIFLUOROETHANE. |
| CN201780057068.5A CN109789126B (en) | 2016-09-19 | 2017-09-18 | pharmaceutical composition |
| UAA201902770A UA123919C2 (en) | 2016-09-19 | 2017-09-18 | Pharmaceutical composition |
| BR112019005133-3A BR112019005133B1 (en) | 2016-09-19 | 2017-09-18 | PHARMACEUTICAL COMPOSITION, METERED-DOSE INHALER, AND METHODS FOR IMPROVING THE CHEMICAL STABILITY OF A PHARMACEUTICAL COMPOSITION, AND FOR IMPROVING THE AEROSOL DISPERSION PERFORMANCE OF A PHARMACEUTICAL COMPOSITION |
| EP19199780.8A EP3607936B1 (en) | 2016-09-19 | 2017-09-18 | Pharmaceutical composition comprising glycopyrrolate |
| CN202210090190.5A CN114515284A (en) | 2016-09-19 | 2017-09-18 | Pharmaceutical composition |
| IL265360A IL265360B2 (en) | 2016-09-19 | 2019-03-13 | Pharmaceutical composition |
| MX2021009475A MX2021009475A (en) | 2016-09-19 | 2019-03-15 | Pharmaceutical composition. |
| SA519401336A SA519401336B1 (en) | 2016-09-19 | 2019-03-17 | Pharmaceutical composition |
| CONC2019/0002556A CO2019002556A2 (en) | 2016-09-19 | 2019-03-19 | Pharmaceutical composition |
| ZA2019/02053A ZA201902053B (en) | 2016-09-19 | 2019-04-02 | Pharmaceutical composition |
| US16/582,993 US11179366B2 (en) | 2016-09-19 | 2019-09-25 | Pharmaceutical composition |
| US16/582,973 US11103480B2 (en) | 2016-09-19 | 2019-09-25 | Pharmaceutical composition |
| JP2020040655A JP7041703B2 (en) | 2016-09-19 | 2020-03-10 | Pharmaceutical composition |
| AU2020202626A AU2020202626B2 (en) | 2016-09-19 | 2020-04-17 | Pharmaceutical composition |
| US17/361,819 US11826348B2 (en) | 2016-09-19 | 2021-06-29 | Pharmaceutical composition |
| US17/361,851 US11826349B2 (en) | 2016-09-19 | 2021-06-29 | Pharmaceutical composition |
| US17/361,772 US11642330B2 (en) | 2016-09-19 | 2021-06-29 | Pharmaceutical composition |
| AU2021205045A AU2021205045C1 (en) | 2016-09-19 | 2021-07-14 | Pharmaceutical composition |
| US17/467,778 US11690823B2 (en) | 2016-09-19 | 2021-09-07 | Pharmaceutical composition |
| JP2022022292A JP7228726B2 (en) | 2016-09-19 | 2022-02-16 | Pharmaceutical composition |
| US18/489,133 US20240050404A1 (en) | 2016-09-19 | 2023-10-18 | Pharmaceutical composition |
| US18/489,150 US20240050405A1 (en) | 2016-09-19 | 2023-10-18 | Pharmaceutical composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1615917.0A GB2558191A (en) | 2016-09-19 | 2016-09-19 | Pharmaceutical composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB201615917D0 true GB201615917D0 (en) | 2016-11-02 |
| GB2558191A GB2558191A (en) | 2018-07-11 |
Family
ID=57288780
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB1615917.0A Withdrawn GB2558191A (en) | 2016-09-19 | 2016-09-19 | Pharmaceutical composition |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB2558191A (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2584686A (en) * | 2019-06-11 | 2020-12-16 | Mexichem Fluor Sa De Cv | Methods |
| PE20221867A1 (en) * | 2020-01-28 | 2022-12-02 | Chiesi Farm Spa | PRESSURIZED METERED DOSE INHALERS COMPRISING A BUFFERED PHARMACEUTICAL FORMULATION |
| GB2597755A (en) * | 2020-08-03 | 2022-02-09 | Mexichem Fluor Sa De Cv | Pharmaceutical composition |
| WO2024157282A1 (en) * | 2023-01-24 | 2024-08-02 | Cipla Limited | Pharmaceutical compositions of green propellant |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014505717A (en) * | 2011-02-17 | 2014-03-06 | シプラ・リミテッド | Pharmaceutical composition |
| GB201108039D0 (en) * | 2011-05-13 | 2011-06-29 | Mexichem Amanco Holding Sa | Compositions |
-
2016
- 2016-09-19 GB GB1615917.0A patent/GB2558191A/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| GB2558191A (en) | 2018-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL265260B (en) | Pharmaceutical composition | |
| IL265360B (en) | Pharmaceutical composition | |
| IL262654A (en) | Pharmaceutical composition | |
| IL271986B1 (en) | Pharmaceutical composition | |
| IL265349A (en) | Pharmaceutical composition | |
| GB201712159D0 (en) | Pharmaceutical composition | |
| GB201521462D0 (en) | Pharmaceutical composition | |
| HUE068810T2 (en) | Pharmaceutical composition | |
| IL272419A (en) | Pharmaceutical composition | |
| GB201719447D0 (en) | Pharmaceutical composition | |
| IL263040A (en) | Pharmaceutical composition comprising eteplirsen | |
| PL3646867T3 (en) | Pharmaceutical composition | |
| PL3454838T3 (en) | Pharmaceutical composition | |
| GB201615917D0 (en) | Pharmaceutical composition | |
| GB201515310D0 (en) | Pharmaceutical composition | |
| GB201615914D0 (en) | Pharmaceutical composition | |
| GB201520862D0 (en) | Pharmaceutical composition | |
| IL263999A (en) | Pharmaceutical compositions | |
| GB201615910D0 (en) | Pharmaceutical composition | |
| IL265436B (en) | Pharmaceutical composition | |
| ZA201705782B (en) | Pharmaceutical compositions | |
| PL3424500T3 (en) | Pharmaceutical composition comprising famitinib | |
| GB201620519D0 (en) | Pharmaceutical composition | |
| IL265428A (en) | Pharmaceutical composition | |
| PT3476391T (en) | Pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |